Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 5/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 5/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | RARG | P13631 | 9/20 | 0.43 |
| ▸ | RARA | P10276 | 8/20 | 0.43 |
| ▸ | RARB | P10826 | 8/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18152400 | 0.91 | BCL9 (0.46) | BCL9CTNNB1SYKSCN9APDK2 | |
| SCHEMBL18165177 | 0.91 | BCL9 (0.48) | BCL9CTNNB1SYKSCN9APDK2 | |
| SCHEMBL18152551 | 0.90 | BCL9 (0.48) | BCL9CTNNB1RARGRARARARB | |
| SCHEMBL18152574 | 0.87 | BCL9 (0.46) | BCL9CTNNB1RARGRARARARB | |
| SCHEMBL18152403 | 0.87 | PDK2 (0.42) | SCN9APDK2CA12CA1CA2 | |
| SCHEMBL18165099 | 0.86 | CA12 (0.45) | BCL9CTNNB1SCN9APDK2CA12 | |
| SCHEMBL926919 | 0.84 | RAB9A (0.49) | SCN9APDK2CA12CA1CA2 | |
| SCHEMBL18152368 | 0.81 | BCL9 (0.60) | BCL9CTNNB1 | |
| SCHEMBL18165160 | 0.81 | CA12 (0.47) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL17958070 | 0.81 | PTPN11 (0.48) | SCN9APDK2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2018-04-05 | — | — | US | disclosed |
| WO-2016168524-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168524-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | BCL9, BCL9L, BCL3 | BCL9 1/4885CTNNB1 4/4885SYK 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.